Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EUROPA
2023-508094-88-00Phase 3Authorised
- Sponsor
- Università degli Studi di Firenze
- Start
- Feb 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of anastrozole, letrozole, exemestane and tamoxifen in breast cancer (2 arms), sponsored by Università degli Studi di Firenze. Primary endpoints: Ipsilateral breast tumor recurrence rate at 5 years and Global health status / quality of life (QLQ-C30 GHS) at 24 months. Planned start Feb 2021; status: authorised.
02
Drugs
anastrozoleletrozoleexemestanetamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-508094-88-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508094-88-00.